Charles River Laboratories International presents a distinctive financial profile characterized by negative profitability metrics amid revenue stability, trading at $232.51 near the upper boundary of its 52-week range of $144.26–$242.73. The systematic screening reveals a negative ROE of -5.74% and net margin of -4.59%, indicating operational headwinds within the life sciences tools sector despite the company's established market presence reflected in its $11.2 billion market capitalization.

The fundamental analysis highlights several contrasting dynamics:

• Revenue resilience: Year-over-year revenue growth of 0.11% demonstrates stability during a challenging operating environment, while the gross margin of 34.46% suggests retained pricing power in specialized laboratory services
• Valuation positioning: The price-to-sales ratio of 2.79 and price-to-book of 3.16 reflect market expectations for operational recovery, particularly given the current absence of positive trailing earnings
• Balance sheet structure: A debt-to-equity ratio of 0.68 and current ratio of 1.29 indicate manageable leverage with adequate short-term liquidity for operations

Key risks include the negative EPS of $-3.76 and operating margin compression to just 1.75%, both flagging execution challenges in translating revenue into bottom-line results. The elevated beta of 1.37 signals amplified volatility relative to broader markets.

Relative to peers West Pharmaceutical Services (WST), Medpace Holdings (MEDP), and Thermo Fisher Scientific (TEM), systematic screening places CRL in a transitional position where valuation metrics anticipate margin recovery while current profitability metrics trail sector standards. The research perspective centers on operational inflection catalysts within contract research services.